Taysha Gene Therapies Stock Soars 7.91% on Clinical Trial Success!

Taysha Gene Therapies, Inc. rose 7.91% in premarket trading. The company announced details for an oral presentation at a symposium, including clinical cohort data from high and low dose TSHA-102 trials, caregiver research supporting FDA alignment on primary endpoint, and preclinical data on broad biodistribution of AAV9 gene therapy vectors. These developments indicate progress in the company's lead clinical program for treating Rett syndrome, contributing to the stock's positive movement.